Specifically, the CAD risk variant alters the rate of regulatory phosphorylation of NIPA by Cyclin-B1-CDK1, decreasing the level of NIPA phosphorylation in cells of the risk genotype (Fig. 1C). This evidence concerns the gene CCNB1 and coronary artery disorder.